Skip to main content
. Author manuscript; available in PMC: 2023 Aug 1.
Published in final edited form as: Nat Mater. 2023 Mar 20;22(7):818–831. doi: 10.1038/s41563-023-01472-w

Table 1 |.

RNA therapeutics approved for clinical use

Product name RNA type Carrier Target Administration route Indication
Onpattro siRNA Lipid nanoparticle TTR Intravenous infusion Polyneuropathy of hATTR amyloidosis
Givlaari siRNA GalNAC conjugation 5-Aminolevulinic acid synthase Subcutaneous injection Acute hepatic porphyria
Oxlumo siRNA GalNAC conjugation Hydroxyacid oxidase 1 Subcutaneous injection Primary hyperoxaluria type 1
Leqvio siRNA GalNAC conjugation PCSK9 Subcutaneous injection Primary hypercholesterolemia or mixed dyslipidaemia
Amvuttra siRNA GalNAC conjugation TTR Subcutaneous injection Polyneuropathy of hATTR amyloidosis
Comirnaty mRNA Lipid nanoparticle SARS-CoV-2 spike protein Intramuscular injection COVID-19
Spikevax mRNA Lipid nanoparticle SARS-CoV-2 spike protein Intramuscular injection COVID-19

hATTR, hereditary transthyretin-mediated amyloidosis; PCSK9, proprotein convertase subtilisin/kexin type 9; TTR, transthyretin.